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Background: Crimean-Congo haemorrhagic fever virus 
(CCHFV) is considered an emerging infectious disease 
threat in the European Union. Since 2000, the inci-
dence and geographic range of confirmed CCHF cases 
have markedly increased, following changes in the 
distribution of its main vector, Hyalomma ticks. Aims: 
To review scientific literature and collect experts’ 
opinion to analyse relevant aspects of the laboratory 
management of human CCHF cases and any exposed 
contacts, as well as identify areas for advancement 
of international collaborative preparedness and labo-
ratory response plans. Methods: We conducted a lit-
erature review on CCHF molecular diagnostics through 
an online search. Further, we obtained expert opin-
ions on the key laboratory aspects of CCHF diagnosis. 
Consulted experts were members of two European 
projects, EMERGE (Efficient response to highly dan-
gerous and emerging pathogens at EU level) and EVD-
LabNet (Emerging Viral Diseases-Expert Laboratory 
Network).Results: Consensus was reached on relevant 
and controversial aspects of CCHF disease with impli-
cations for laboratory management of human CCHF 
cases, including biosafety, diagnostic algorithm and 
advice to improve lab capabilities. Knowledge on the 
diffusion of CCHF can be obtained by promoting syn-
dromic approach to infectious diseases diagnosis and 
by including CCHFV infection in the diagnostic algo-
rithm of severe fevers of unknown origin. Conclusion: 
No effective vaccine and/or therapeutics are available 
at present so outbreak response relies on rapid iden-
tification and appropriate infection control measures. 
Frontline hospitals and reference laboratories have a 
crucial role in the response to a CCHF outbreak, which 
should integrate laboratory, clinical and public health 
responses.
Introduction
Crimean-Congo haemorrhagic fever virus (CCHFV) is 
a tick-borne pathogen that causes a frequently lethal 
disease in humans and is considered to be a major 
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emerging infectious disease threat spreading to and 
within Europe [1-3].
The severity of the disease, the presence of domes-
tic and wild animal reservoirs and/or vectors, a large 
population of susceptible humans, limited diagnos-
tic capacities and resources for epidemiological/
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Crimean-Congo haemorrhagic fever virus strains with complete S segment available as at 5 December 2017, were collected from GenBank 
database and clustered at 100% with CD-HIT v4.6. Sequences were aligned with MAFFT v7.123b. Phylogenetic analysis were performed using 
RAxML v8.2.10 with GTRGAMMA model and 1,000 bootstrap inferences. For graphical exemplification, only representative sequences in each 
clade for each country were selected and reported in the phylogenetic tree.
Branches owing to different clades are presented in the following colours: Africa: clade I (red), clade II (light green) and clade III (brown); Asia: 
clade IV (dark green); Europe: clade V (purple), clade VI (light blue) and clade VII (blue). For each strain we reported GenBank ID, isolate ID, 
host, country and collection date, if present. Bootstrap values are shown for each clade.
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ecological investigation, as well as the absence of 
effective prophylaxis and treatment render CCHFV a 
pathogen with outbreak potential [4].
Since 2000, the incidence and geographic range of 
CCHF cases have markedly increased [5,6] following 
an expanding distribution of its main vector, ticks 
of the genus  Hyalomma, specifically the  Hyalomma 
marginatumspecies [1,7,8]. In Turkey, nearly 900 new 
CCHF cases occur annually, with a total of 9,787 cases 
reported from 2002–15 [9]. CCHF is endemic in the 
Balkan region, in Kosovo, 228 cases were reported 
from 1995–2013 [10], In Bulgaria, over 1,500 cases have 
been reported from 1952 [11]. In the European region, 
cases of human infection have also been reported 
from Albania, Russian Federation, Georgia, Greece, 
and Ukraine [12]. Imported cases have been reported 
in France [13], United Kingdom [14], Greece [15] and 
Germany [16]. A detailed review of other outbreaks has 
been recently published by Papa et al. [11].
Public health systems (including diagnostic laborato-
ries) should be prepared to respond to the increased 
circulation of the virus in endemic EU countries, the 
potential for importation of human CCHF cases or the 
emergence of virus circulation in new areas e.g. Spain 
[17].
The objectives of this study were to amalgamate 
the expertise of two EU expert networks (i) EMERGE 
(Efficient response to highly dangerous and emerg-
ing pathogens at EU level) [18] and (ii) EVD-LabNet 
(Emerging Viral Diseases Laboratory Network) [19], 
in order to select and analyse the relevant and some 
of controversial aspects of CCHF disease diagnostics 
with implications for laboratory management of human 
CCHF cases and any exposed contacts.
Methods
We carried out an on line research of published 
paper related to CCHFV molecular detection meth-
ods. References were obtained by an online search in 
PubMed using an intentionally wide search-query to 
Figure 2
World map of Crimean-Congo haemorrhagic fever virus distribution (n = 163)
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Based on all available complete S segment CCHFV genomes (163 sequences as at 5 December 2017) retrieved from GenBank.
For all strains analysed, the collection countries are presented in the following colours: Africa: clade I (red), clade II (light green) and clade III 
(brown); Asia: clade IV (dark green); Europe: clade V (purple), clade VI (light blue) and clade VII (blue).
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ensure that a large number of papers was retrieved 
also for a rare disease such as CCHF.
The query produced a large number of papers, 20% of 
them were discarded after a narrative review, as they 
did not contain a detailed description of the detection 
methods employed including the nucleotide sequences 
of primers and/or probes. The search was done by one 
author and the results discussed among the authors. 
Papers related on non-previously retrieved molecular 
detection methods or to others relevant aspects dis-
cussed in this report have been directly provided by 
experts. For phylogenetic analysis all available CCHF 
virus genomes by 5 December 2017 were retrieved from 
GenBank (https://www.ncbi.nlm.nih.gov/nucleotide), 
using ‘txid1980519(Organism)’ as term of query. All 
analyses have been focused only on CCHFV S-segment, 
because it resulted as the most conserved gene across 
CCHFVs [8,20] and also because mostly all retrieved 
molecular methods has S segment as target. CCHF 
virus strains with complete S segment were selected 
and clustered at 100% with CD-HIT v4.6. A total of 163 
sequences available at 5 December 2017 were obtained 
and aligned with MAFFT v7.123b in local pair mode. 
Phylogenetic analysis were performed with RAxML 
v8.2.10 using GTRGAMMA model and 1000 bootstrap 
inferences.
A preliminary text was drafted and discussed among 
the experts by email and during EMERGE and EVD-
LabNet networks’ 2017 and 2018 annual meetings. 
Most of the relevant and some of controversial aspects 
of CCHF disease with implications for laboratory man-
agement have been selected and analysed in the fol-
lowing sections. In the present paper, all the expressed 
opinions take into account both published data and 
personal experience of the experts.
Results
Crimean-Congo haemorrhagic fever virus 
clades distribution
CCHFV (family  Nairoviridae, genus  Orthonairovirus) is 
tick-borne and is maintained in a tick-vertebrate-tick 
cycle with Hyalomma marginatum, the main vector spe-
cies in Europe. Given the wide distribution of its vec-
tor, CCHFV has been detected over a wide geographic 
range: Africa, Europe, Asia and the Middle East [5,21].
CCHFV is an enveloped, tri-partite, negative-sense, RNA 
virus. The large genome segment (L) encodes the RNA-
dependent RNA polymerase (L protein), the medium 
segment (M) encodes the glycoproteins GN and GC, 
while the small segment (S) encodes the nucleocapsid 
protein (N).
Phylogenetic tree (Figure 1) was built, including only 65 
of 163 representative strains with reported location of 
provenance either in GenBank records or in the asso-
ciated papers. Taking into account similarity and geo-
graphic locations of the different viral lineages, seven 
genetic clades were identified: three prevalently dif-
fused in Africa (clades I-III), three in Europe (clades V, 
VI and VII) and one in the south of Asia (clade IV). 
Most of the isolates causing outbreaks in eastern 
Europe belong to clade V, whereas clade VI and VII 
include largely divergent strains isolated from ticks in 
Greece (including the prototype strain AP92) [21,22] 
and Russia (GenBank accession number KR814833 and 
KR814835).
Moreover, isolates belonging to the African clade III 
were collected from infected ticks in 2010 and 2014, 
and recently [23] a virus aligning to this clade was the 
cause of an outbreak in Spain [17].
For all strains analysed, the collection country was 
recorded and represented on the world map in  Figure 
2.
Transmission mode
Human infections are usually observed as single, spo-
radic cases when people in rural areas are bitten by 
ticks that have become infected by feeding on virae-
mic wild and domestic animals like hares, hedgehogs, 
horses, livestock and possibly birds [21]. The infection 
in animals is generally asymptomatic; at most, a mild 
fever may be noted.
In addition to tick exposure, CCHF infection can result 
from direct contact, especially through mucous mem-
branes or skin wounds, with crushed infected ticks or 
the blood of infected animals (principally among shep-
herds, farmers, abattoir workers and veterinarians). 
Person-to-person transmission can also occur through 
contact with virus-containing bodily fluids of patients 
during the first 7–10 days of illness [21]. Unprotected 
contact with other bodily fluids like saliva or urine, may 
also represent a risk for humans [24]. Nosocomial trans-
mission to healthcare workers, transmission among 
patients sharing the same room [25] and possible sex-
ual transmission [26,27] have also been reported.
Relevance of viraemia
The typical duration of viraemia ranges from 1– 9 days 
[28,29], and there is so far no evidence of detectable 
viraemia during the incubation period [30]. However, 
the positivity of CCHFV RNA in serum has been excep-
tionally reported up to 36 days from the onset of 
symptoms [31]. Studies investigating the presence and 
persistence of CCHFV in other body fluids are limited. 
Viral RNA was detectable up to 10 days and as late 
as 25 days after onset of symptoms in saliva [24] and 
urine [31] respectively, but no data on virus viability 
are available.
Viral load is the most important prognostic fac-
tor: a value of viraemia higher than 108  copies/mL 
is associated with fatal outcomes [32]. Viraemia 
decreases significantly over time in surviving patients, 
but remains persistently high in non-survivors [32,33].
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Antibody kinetics
All CCHFV genotypes belong to one serogroup [21]. 
Cross-reactivity between CCHFV and other nairovi-
ruses infecting humans ( Erve virus [34]), has not been 
described, although monoclonal and polyclonal anti-
bodies to the N protein of CCHFV were found to cross-
react weakly with Dugbe virus N protein [35].
Nucleocapside-directed IgM antibodies have been 
identified as the initial serological marker during infec-
tion, becoming detectable in a median of 2–3 days 
after disease onset, followed by glycoprotein precursor 
(GPC) directed IgM (4–6 days) and IgG antibodies (5–6 
days) [28]. In another report, CCHFV IgM was detect-
able from 4 days after the onset of disease for up to 
4 months. The maximum level of antibody titres was 
usually reached in the second to third week of illness 
[1]. IgM titre typically declines to undetectable levels 4 
months after the onset of symptoms [29].
IgG seroconversion occurs 1–2 days after the IgM 
response [28] and IgG antibody remains detectable for 
at least 5 years [29,36].
Antibody production against CCHFV is an impor-
tant prognostic indicator for survival [37]. Patients 
with fatal outcome rarely develop measurable anti-
body responses (reviewed in [37]) and Saksida et al. 
observed a reverse correlation between viral load and 
antibody levels in fatal CCHF cases [33], indicating that 
an impaired immune response leads to uncontrolled 
replication of the virus. High levels of interleukin-10 
(IL-10), an anti-inflammatory cytokine, were detected 
in patients with fatal outcomes and were lowest in 
patients with a moderate disease course [33]. It was 
hypothesised that CCHF could be the result of a delayed 
and downregulated immune response caused by IL-10, 
which leads to an increased replication and spread of 
CCHFV throughout the body [33].
Biosafety
CCHFV is classified as a risk group 4 pathogen. The 
virus is stable under wet conditions for 7 hours at 
37 °C, 11 days at 20 °C and 15 days at 4 °C [20]. Under 
dry conditions, it is stable for at least 90 min, but less 
than 24 hours.
However, there is an ongoing debate about the abso-
lute requirement of biosafety levels 4 (BSL4) for han-
dling the virus [38]. Many endemic countries need to 
work with the virus despite the absence of BSL4 infra-
structure. Biosafety and biosecurity procedures are 
essential for the safe and appropriate management of 
specimens from suspected/confirmed CCHF patients. 
All laboratories should refer to national guidelines on 
the documents ‘CWA 15793:2011 Laboratory bio-risk 
management’ and ‘CWA 16393:2012 Laboratory bio-
risk management - Guidelines for the implementation 
of CWA 15793:2008’ for a complete guide [39]. The 
European Check List for Laboratory Biorisk Management 
developed in the framework of the Joint Actions Quality 
Assurance Exercises and Networking on the Detection 
of Highly Infectious Pathogens (QUANDHIP) project can 
be helpful for the implementation and evaluation of 
biorisk management approaches [40].
Inactivation
Like all lipid-enveloped viruses, CCHFV can be readily 
inactivated by common fixatives such as 2% glutaral-
dehyde [41], formalin and paraformaldehyde; chlorine-
based disinfectants, such as 1% sodium hypochlorite 
[41,42]; and other disinfectants, such as hydrogen per-
oxide and peracetic acid [43,44]. Physical inactivation 
is also effective, like high temperature (56 °C for 30 
min or 60 °C for 15 min) [41], Ultraviolet (1,200 to 3,000 
μW/cm2) or low pH (less than 6) [43,45]. The virus does 
not survive in matured meat (due to low pH) and is also 
inactivated in 40% ethanol within 2 min [20].
There is a general agreement among the consulted 
experts that a critical aspect for laboratory biosafety 
and operation is the proper and reliable inactivation of 
specimens before they can be removed from the high-
level biocontainment environment for further diagnos-
tic testing. Some of these inactivation methods include 
(i) chemical treatment (i.e. Buffer AVL or Buffer RLT, 
Qiagen, Hilden, Germany)  + 100% ethanol, SDS, 0.5% 
Tween-20 (Thermofisher,  Waltham, Massachusetts, 
USA) [46,47] or (ii) heat treatment plus riboflavin (vita-
min B2) [48].
It is opinion of the experts that further evaluation of 
inactivation procedures are needed, especially for their 
impact on other laboratory tests necessary for clinical 
evaluation and increased survival rates of patients. 
Although there is no direct evidence of its effects on 
CCHFV, it has been shown that Triton X-100 (Sigma-
Aldrich, Saint Louis, Missouri, USA can decrease the 
biohazard risk of performing laboratory tests on sam-
ples from patients infected with other haemorrhagic 
fever viruses (i.e. Ebola), without affecting the results 
of biochemical tests [49-52].
Transport of diagnostic samples
General guidelines for suspected viral haemorrhagic 
fever infections apply for the transport of diagnostic 
samples from CCHF-suspected cases; these are listed 
under guidelines as Category A, Infectious Substances 
Affecting Humans UN 2814 and must be transported 
in packaging that meets the United Nations class 6.2 
specifications and complies with Packing Instruction 
P620 [53].
Additionally, as for other biological resources, the 
exchange of CCHF samples or virus strains needs to 
comply with the Nagoya protocol on access to genetic 
resources and the fair and equitable sharing of bene-
fits arising from their utilisation, which regulates trans-
national exchange between countries [54].
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Diagnosis
The choice of which CCHF detection assays should be 
used for diagnostics with maximum sensitivity and 
specificity depends on the stage of disease and the 
specimens available.
Laboratory diagnosis of a patient with a clinical history 
compatible with CCHF is generally performed during 
the acute phase of the disease by viral RNA (RT-PCR) 
detection in blood [21]. In addition to blood (serum, 
plasma or whole blood), other possible specimens for 
molecular detection are saliva, urine [24,32] or post 
mortem biopsy of the liver and bodily fluids (including 
semen, for infection control purposes) [26,27].
The available data, limited to very few patients, do not 
allow detailed comparisons of the sensitivity of RT-PCR 
detection methods performed on different sample 
types and, in particular, of urine and saliva vs serum 
samples. In two of six infected patients reported in 
a review of CCHF cases in Kosovo* [31], viraemia was 
detectable up to 30 days after the onset of symptoms. 
In the same investigation, one patient’s urine was 
PCR-positive before the serum, and in another patient 
viruria continued longer than viraemia; however, more 
detailed studies on viruria are required. Further, both 
viruria and viraemia are detectable several days after 
the appearance of IgG response [31]. No chronological 
data are provided about detection of CCHFV RNA in 
saliva [24].
During the small outbreak in Spain involving two 
patients in 2016, positive RT-PCR results were obtained 
via saliva and vaginal swab, but they became negative 
when viraemia was still detectable [17]. Virus isolation 
was attempted from these samples, but was not suc-
cessful (Maria Paz Sanchez-Seco, personal commu-
nication, EVD-LabNet 2ndannual meeting, Rotterdam 
October 2017).
Molecular detection
There is high genetic diversity within the different 
CCHFV strains (Figure 1), which consequently hampers 
the performance of molecular tests. As a result, a range 
of different methods employing varied primer/probe 
combinations have been developed and a truly uni-
versal assay has been difficult to devise.  Table 1  lists 
published molecular assays retrieved by our PubMed 
search: two single round PCR, six nested PCR, 10 real-
time PCR, one loop-mediated isothermal amplification 
(LAMP) and one recombinase polymerase amplification 
(RPA). Indication on reference testing materials and 
sensitivity/specificity of the tests are also reported, 
when declared.
Therefore there is an agreement of experts that is advis-
able to perform more than one test to avoid exclusive 
Table 2
Commercial serological assays for Crimean-Congo haemorrhagic fever virus detection as at 5 December 2017
          Assay Detection mode Diagnostic kit producers Comments/Target antigen
IgG ELISA
Vector-Best, Novosibirsk, Russia Unknown
IgM ELISA Qualitative
IgG IFA test 
 
Ag detection
IgG ELISA Qualitative
Euroimmun, Luebeck, Germany CCHFV GPC and CCHFV NIgM ELISA
IgG IFA
IgG ELISA
Crimean-Congo ELISA Kits, Diagen 
Biyoteknolojik Sistemleri A.Ş., Ankara, Turkey UnknownIgM ELISA Quantitative
Ag ELISA
IgG ELISA Qualitative
Abbexa Ltd, Cambridge, United Kingdom For research use only, not for diagnostic use.IgM ELISA
Elisa
IgG ELISA Quantitative
Alpha Diagnostic Intl. Inc., San Antonio, Texas, 
United States(US)
For research use only, not for 
diagnostic or therapeutic use. 
 
CCHFV NP
IgM ELISA Quantitative
IgA, IgG, IgM ELISA Qualitative
IgG ELISA Qualitative ELISA Kit, Antibody-Sunlong Biotech Co.,Ltd, 
Hangzhou, Zhejiang, China UnknownELISA
IgG ELISA Qualitative
Creative Diagnostics, Shirley, New York, USA CCHFV NP
IgM ELISA Quantitative, qualitative
CCHFV: Crimean-Congo haemorrhagic fever virus; ELISA: enzyme-linked immunosorbent assay; IFA: immunofluorescent assay; USA: United 
States of America.
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reliance on a single assay and a single target, taking 
into account the travel history and the geographic dis-
tribution of the different strains.
Serological assays
In published investigations, the methods employed for 
the detection of antibodies are indirect immunofluores-
cence assays (IFAs) and enzyme-linked immunosorbent 
assays (ELISAs) [55-57]. Several commercial kits are 
available (Table 2), but only the performance of Vector-
Best CCHF ELISA and Euroimmun CCHF IFA have been 
tested in a collaborative study conducted by reference 
centres for CCHF laboratory diagnosis and surveillance 
in their respective countries [58]. The IgM sensitivity 
for ELISA and IFA assays were 87.8% (95% CI: 78.6–
96.9).and 93.9% (95% CI: 85.8–100.0), respectively. 
For IgG assays, reported sensitivities were 80.4% (95% 
CI: 69.5–91.3) for ELISA and 86.1% (95% CI: 74.8–97.4) 
for IFA. The overall specificity was estimated at 100% 
for all the tests.
A CCHFV seroneutralisation test is not normally per-
formed for diagnostic purposes; it requires work with 
an infectious virus, necessitating a BSL4 laboratory, 
and is difficult to perform. However, reverse genetic 
approaches employing non-infectious reporter viruses 
have been described recently [59], enabling neutralisa-
tion to be performed at low containment.
Virus isolation
Viral isolation, i.e. from blood or organ for further char-
acterisation or infectivity studies, is performed under 
BSL4 conditions on either LLC-MK2, Vero, BHK-21 or 
SW-13.4 cell lines and can be achieved in 2–10 days 
[60]. CCHFV generally produces no or little cytopatho-
genic effect and viral growth can be detected by IFA 
with specific monoclonal antibodies [41] or by molec-
ular tests. When viral isolation on cell cultures fails, 
it can be attempted in new-born or immunodeficient 
mice.
It is preferable that viral isolation is performed on sam-
ples collected during the first 5 days of infection, when 
the viraemia levels are high [58,61].
Laboratory diagnosis of CCHFV infection
There is no official, agreed-upon case definition for 
CCHF in the EU, though several case definitions adopted 
by EU countries were reviewed by the European Centre 
for Disease Prevention and Control (ECDC) [62,63]. 
According to a report published by ECDC in 2014 [60], 
most countries used, at least for surveillance pur-
poses, the EU case definition established for Viral 
Haemorrhagic Fever [64].
Taking into account that laboratory screening is usu-
ally performed using molecular methods, we propose 
as expert opinion the following molecular diagnostic 
Box
Criteria proposed for laboratory confirmation of a 
clinically suspected Crimean Congo haemorrhagic fever 
case 
For laboratory confirmation of a clinical CCHF diagnosis, the 
expert group opinion is that a CCHFV infection is laboratory 
confirmed when at least one criteria in the Box is fulfilled.
• Detection by molecular tests of CCHFV RNA, in blood 
(whole blood, serum or plasma) or in other bodily fluids or 
tissues;
• Detection of CCHFV IgM or relevant (fourfold) increase in 
CCHFV IgG titres between two serologic samples (acute and 
convalescence phases);
• CCHFV isolation and/or detection of CCHF viral antigens in 
blood (whole blood, serum or plasma).
CCHFV: Crimean Congo haemorrhagic fever virus.
Figure 3
Algorithm for molecular diagnosis of Crimean-Congo 
haemorrhagic fever acute infection based on expert 
opinion
Blood (Other additional samplea)
Molecular testb
Negative
Negative
Symptom onset
0-3 days 
request a second 
sample only for high 
risk exposure pointc
NO
CCHFV
infection
Confirmed 
CCHFV 
infection
Confirmed CCHFV 
infection
No
CCHFV
infection
>3 days 0-3 days >3 days
Symptom onset
Positive
Positive Sequencingb
Sequencingb
CCHFV: Crimean-Congo haemorrhagic fever virus.
a The preferred biological specimen is blood (serum, plasma or 
whole blood). Other possible biological specimens are saliva, 
urine [24,31] and post-mortem biopsy or bodily fluids (including 
semen, for infection control purposes [26,27]).
b It is preferable that at least two different targets are tested: 
The first molecular test should target the S segment, while the 
second assay should be performed in a different genome region 
to confirm the absence or presence of CCHF infection, in case of 
negative result.
c Sequencing is indicated for viral characterisation and cluster 
identification, as well as for the confirmation of first cases 
detected or of discordant results of molecular tests.
d The molecular test to be performed should take into account 
epidemiological data.
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algorithm for patients with suspected CCHF infection 
(Figure 3). However, it is advisable, especially when the 
molecular tests are negative, to perform also serologi-
cal tests on all suspected patients.
Other relevant aspects related to management of CCHF 
patients as clinical manifestation and discharging cri-
teria are reported in the Supplementary material.
Discussion
CCHF is an important global health threat, as under-
lined by its inclusion in the list of priority diseases in 
the WHO document ‘An R & D blueprint for action to 
prevent epidemics’ [65].
In Europe, two autochthonous cases in Spain in 2016 
[17] and the observed risk of importation of travel-
associated cases [66] reinforce the notion that public 
health systems must be ready to respond to a potential 
emergence of CCHF.
Prompt and accurate laboratory diagnosis during the 
first days of the disease is critical to improve patient 
management, guide infection control measures and 
reduce case fatality. Early detection of viral RNA in 
blood is considered the gold standard diagnostic 
approach in the acute phase of the disease [21]. While 
the CCHFV RNA RT-PCR diagnostic test is most com-
monly performed in specialised laboratories, where 
non-commercial diagnostic assays and related refer-
ence biological material are available, this capability is 
more limited in rural areas and small cities where the 
majority of reported cases have occurred [9]. The avail-
ability of simple to use, commercial diagnostic tests will 
increase the number of laboratories performing RT-PCR 
or a similar NA detection strategy. However, labora-
tory capacity does not automatically mean capability, 
and laboratories implementing such tests would ben-
efit from external quality assessments (EQA) of their 
capability to detect CCHFV in clinical samples, includ-
ing monitoring of the effects of any corrective actions 
taken. The difficulty of clinical laboratories in estab-
lishing the diagnosis a CCHFV infection underlines the 
need to perform confirmatory tests in reference labora-
tories for both positive and negative samples collected 
from patients suspected of CCHF infection.
In addition, appropriate biosafety measures must be in 
place when performing molecular testing.
Proposed measures to improve CCHFV 
laboratory preparedness and response
Measures to improve CCHFV laboratory preparedness 
and response should include: improving molecular 
tests to overcome the lack of sensitivity due to the 
high variability of the CCHFV genome; providing a posi-
tive control panel for molecular diagnostics, including 
the different CCHFV genotypes (including for serol-
ogy testing) in order to support the improvement of 
diagnostic capability of clinical laboratories; enroll-
ing diagnostic laboratories appointed for CCHFV diag-
nostics regularly in EQA programmes; improvement of 
diagnostic algorithms building on clinical experiences; 
validation of procedures to inactivate infectivity of 
clinical samples; and establishing of an international 
biorepository for the collection and storing of clinical 
samples, with the aim of validating new diagnostic 
tests and supporting pathogenicity studies. Some of 
these activities, including the evaluation of laboratory 
capability [67] and EQA [68] in particular, have been 
performed within the framework of EMERGE and EVD-
LabNet and earlier as part of EU-funded projects such 
as EuronetP4 (Grant No. 2003214), EnP4Lab (Grant No. 
2006208), QUANDHIP (Grant No. 20102102) and ENIVD 
(Framework Service Contract ref. no. ECDC/2008/011. 
Similar support of other collaborating EU projects, 
such as the European Virus Archive (EVAg), could meet 
these needs in the future.
Conclusions
There are knowledge gaps concerning the putative per-
sistence of the CCHFV in various body compartments 
of survivors and the related consequences for infection 
transmission. Basic knowledge is needed to provide 
evidence to better inform hospital discharge guidelines 
and these issues need further research. Furthermore, 
a One Health approach is required for adequate public 
health preparedness for CCHF, and relevant measures 
should include vector and animal surveillance, focus-
ing particularly on migratory birds [5,9,69]. Greater 
awareness of the circulation of CCHFV in vectors/ani-
mals in specific geographic areas is fundamental in 
order to alert public health systems. Information on the 
circulation of CCHFV can be obtained by a syndromic 
approach and by including CCHFV testing in the diag-
nostic algorithm of severe febrile infectious diseases 
of unknown origin.
Until an effective vaccine and/or therapeutics have 
been developed, the CCHFV outbreak response will 
continue to rely on rapid identification and appropri-
ate infection-control measures. Front-line hospitals, as 
well as reference laboratories, have a crucial role in the 
outbreak response, which should integrate laboratory, 
clinical and public health responses.
Note
*This designation is without prejudice to positions on status, 
and is in line with United Nations Security Council Resolution 
1244/99 and the International Court of Justice Opinion on the 
Kosovo Declaration of Independence.
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